For the twelve months ended Sep 30, 2026, Roivant Sciences Ltd. reported $41.08M of revenue and -$445.12M of net income.
ROIV revenue was $35.12M in fiscal Q2 2026 (ended Sep 30, 2026), up about 22-fold from a year earlier and up about 24-fold from the prior quarter. For the full fiscal 2025 it was $8.26M, down 71.6% from fiscal 2024. Compound annual growth was -19.1% over 5 years. It rose in 2 of the last 5 fiscal years.
ROIV net income was -$191.62M in fiscal Q2 2026 (ended Sep 30, 2026), compared with -$113.52M a year earlier. For the full fiscal 2025 it was -$299.77M, compared with -$171.98M in fiscal 2024.
ROIV diluted EPS was -$0.27 in fiscal Q2 2026 (ended Sep 30, 2026), compared with -$0.17 a year earlier. For the full fiscal 2025 it was -$0.54, compared with -$0.24 in fiscal 2024.
ROIV free cash flow was $594.21M in fiscal Q2 2026 (ended Sep 30, 2026), compared with -$193.51M a year earlier. For the full fiscal 2025 it was -$758.56M, compared with -$844.05M in fiscal 2024.
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M |
| Research and development | $681.81M | $550.41M | $439.91M | $454.06M | $483.04M | $236.63M |
| Selling, general and admin | $610.47M | $591.41M | $416.13M | $383.45M | $775.03M | $259.88M |
| Operating income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B | -$1.07B |
| Interest expense | - | - | $34.78M | $27.97M | $7.04M | $2.81M |
| Pre-tax income | -$264.58M | -$681.59M | $4.57B | -$884.99M | -$923.75M | -$898.55M |
| Income tax | $133.33M | $48.17M | $21.50M | $4.08M | $369.0K | $1.69M |
| Net income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M | -$809.23M |
| EPS, basic | -$0.43 | -$0.24 | $5.55 | -$1.42 | -$1.26 | -$1.28 |
| EPS, diluted | -$0.54 | -$0.24 | $5.23 | -$1.42 | -$1.26 | -$1.28 |
| Diluted shares | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M | 630.0M |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.42B | $2.72B | $6.49B | $1.69B | $2.07B | $2.14B |
| Short-term investments | $2.87B | $2.17B | $0 | - | - | - |
| Receivables | - | - | $3.99M | $30.38M | $3.88M | $11.22M |
| Inventory | - | - | $35.25M | $2.76M | $0 | - |
| Current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B | $2.19B |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B | $2.59B |
| Current liabilities | $281.24M | $149.41M | $266.76M | $272.45M | $184.37M | $218.96M |
| Short-term debt | - | - | $12.00M | $40.72M | $0 | $0 |
| Long-term debt | - | - | - | - | $210.03M | $170.28M |
| Total debt | - | - | $430.59M | $375.51M | $210.03M | $170.28M |
| Total liabilities | $416.27M | $249.74M | $773.95M | $782.02M | $523.70M | $527.69M |
| Shareholders' equity | $4.53B | $5.19B | $6.45B | $1.61B | $2.04B | $2.04B |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M | -$552.14M |
| Capital expenditures | $8.21M | $4.60M | $1.38M | $12.69M | $17.44M | $5.81M |
| Free cash flow | -$758.56M | -$844.05M | -$766.65M | -$856.08M | -$695.16M | -$557.94M |
| Investing cash flow | -$682.33M | -$1.77B | $5.20B | -$44.27M | $303.30M | -$31.70M |
| Financing cash flow | $134.24M | -$1.22B | $419.36M | $499.46M | $306.79M | $456.26M |
| Share repurchases | - | $1.29B | $0 | $0 | - | - |
| Stock-based compensation | $346.17M | $289.03M | $199.63M | $217.78M | $564.96M | $84.96M |
| Depreciation and amortization | $3.35M | $14.07M | $22.04M | $18.86M | $5.93M | - |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | -71.6% | -11.2% | 3.8% | -43.0% | 132.3% | - |
| Operating margin | -6235.7% | -3453.3% | 13746.9% | -2875.9% | -2444.8% | -4500.5% |
| Net margin | -3629.2% | -592.0% | 13294.2% | -3200.2% | -1528.9% | -3400.9% |
| Free cash flow margin | -9183.5% | -2905.2% | -2343.6% | -2715.1% | -1257.4% | -2344.8% |
| Return on equity | -6.6% | -3.3% | 67.4% | -62.8% | -41.5% | -39.7% |
| Return on assets | -5.3% | -3.2% | 60.2% | -42.2% | -32.7% | -31.2% |
| Current ratio | 18.37 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 |
| Debt to equity | - | - | 0.07 | 0.23 | 0.10 | 0.08 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.12M | $1.44M | $2.52M | $2.00M | $1.57M | $2.17M | $7.57M | $9.02M | $4.47M | $7.99M | $9.02M | $15.56M |
| Cost of revenue | $3.35M | $284.0K | - | - | $111.0K | $154.0K | - | - | - | - | - | - |
| Gross profit | $31.77M | $1.16M | - | - | $1.46M | $2.02M | - | - | - | - | - | - |
| Research and development | $145.75M | $202.02M | $198.94M | $165.38M | $164.57M | $152.92M | $145.24M | $141.59M | $143.07M | $120.51M | $107.56M | $108.15M |
| Selling, general and admin | $154.08M | $165.53M | $158.25M | $175.07M | $143.13M | $134.02M | $147.09M | $141.54M | $202.88M | $99.89M | $108.10M | $128.17M |
| Operating income | -$268.05M | -$365.99M | $415.24M | -$339.15M | -$306.23M | -$284.92M | -$284.96M | -$274.38M | -$341.71M | -$102.23M | -$206.83M | $5.13B |
| Interest expense | - | - | - | - | - | - | - | - | - | $13.40M | $7.17M | $9.44M |
| Pre-tax income | -$166.34M | -$294.56M | $454.10M | -$290.37M | -$159.04M | -$269.26M | -$203.05M | -$234.51M | -$224.38M | -$19.64M | -$100.73M | $5.15B |
| Income tax | -$13.37M | -$3.96M | $98.35M | $23.33M | $7.00M | $4.65M | $49.32M | -$25.57M | $12.46M | $11.96M | -$5.77M | $22.36M |
| Net income | -$191.62M | -$290.61M | $302.99M | -$265.89M | -$113.52M | -$273.91M | -$206.47M | $169.38M | -$279.92M | $57.49M | -$151.12M | $5.10B |
| EPS, basic | -$0.27 | -$0.26 | $0.45 | -$0.38 | -$0.17 | -$0.33 | -$0.29 | $0.23 | -$0.31 | $0.13 | -$0.04 | $6.37 |
| EPS, diluted | -$0.27 | -$0.26 | $0.34 | -$0.38 | -$0.17 | -$0.33 | -$0.28 | $0.23 | -$0.31 | $0.12 | -$0.02 | $6.03 |
| Diluted shares | 722.8M | 720.8M | - | 696.9M | 680.9M | 680.3M | - | 722.7M | 735.5M | 781.6M | - | 844.5M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.64B | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B | $1.99B | $1.96B | $5.68B | $6.49B | $6.67B |
| Short-term investments | $2.57B | $2.59B | $2.87B | $3.05B | $3.15B | $3.26B | $2.17B | $3.16B | $3.43B | - | $0 | - |
| Receivables | - | - | - | - | - | - | - | $678.0K | $1.92M | $79.79M | $3.99M | $41.08M |
| Inventory | - | - | - | - | - | - | - | - | - | $34.00M | $35.25M | $5.24M |
| Current assets | $4.36B | $4.74B | $5.17B | $4.66B | $4.51B | $4.62B | $5.00B | $5.36B | $5.80B | $6.00B | $6.73B | $6.81B |
| Total assets | $4.98B | $5.31B | $5.71B | $5.23B | $5.06B | $5.03B | $5.44B | $5.79B | $6.21B | $6.50B | $7.22B | $7.31B |
| Current liabilities | $279.91M | $283.60M | $281.24M | $151.96M | $133.86M | $113.87M | $149.41M | $141.48M | $556.25M | $215.04M | $266.76M | $244.90M |
| Short-term debt | - | - | - | - | - | - | - | - | - | $12.00M | $12.00M | $45.71M |
| Total debt | - | - | - | - | - | - | - | - | - | $311.72M | $430.59M | $403.34M |
| Total liabilities | $380.10M | $384.62M | $416.27M | $251.14M | $257.14M | $216.70M | $249.74M | $256.38M | $625.99M | $601.16M | $773.95M | $728.10M |
| Shareholders' equity | $4.02B | $4.92B | $4.53B | $4.27B | $4.81B | $4.82B | $5.19B | $5.54B | $5.58B | $5.90B | $6.45B | $6.58B |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $594.42M | -$270.50M | -$163.82M | -$196.48M | -$185.66M | -$204.38M | -$172.56M | -$207.25M | -$266.81M | -$192.83M | -$108.46M | -$210.45M |
| Capital expenditures | $208.0K | $419.0K | $1.26M | -$4.93M | $7.85M | $4.04M | $811.0K | $1.83M | $996.0K | $965.0K | $349.0K | $355.0K |
| Free cash flow | $594.21M | -$270.92M | -$165.08M | -$201.42M | -$193.51M | -$208.42M | -$173.38M | -$209.08M | -$267.80M | -$193.79M | -$108.81M | -$210.81M |
| Investing cash flow | $42.54M | $281.26M | $173.49M | $109.47M | $120.42M | -$1.09B | $1.07B | $454.07M | -$3.29B | -$965.0K | $6.93M | $5.23B |
| Financing cash flow | -$249.21M | -$181.51M | -$68.78M | $328.19M | $62.59M | -$187.77M | -$177.15M | -$272.95M | -$109.07M | -$660.62M | -$32.62M | $236.64M |
| Share repurchases | $74.47M | $206.73M | - | $0 | $0 | $208.29M | $295.44M | $243.35M | $106.05M | $648.38M | $0 | $0 |
| Stock-based compensation | $79.30M | $83.34M | $77.17M | $105.00M | $81.82M | $82.18M | $83.49M | $83.68M | $71.67M | $50.19M | $46.72M | $54.33M |
| Depreciation and amortization | $604.0K | $600.0K | $638.0K | $691.0K | $921.0K | $1.10M | $1.43M | $2.92M | $4.84M | $4.88M | $5.22M | $5.38M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 2135.6% | -33.5% | -66.7% | -77.8% | -64.9% | -72.8% | -16.1% | -42.1% | 22.7% | -63.1% | - | -8.7% |
| Net income growth, YoY | - | - | - | - | - | - | - | -96.7% | - | - | - | - |
| EPS growth, YoY | - | - | - | - | - | - | - | -96.2% | - | - | - | - |
| Gross margin | 90.5% | 80.3% | - | - | 92.9% | 92.9% | - | - | - | - | - | - |
| Operating margin | -763.2% | -25380.9% | 16477.8% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% | -1279.5% | -2293.1% | 32948.6% |
| Net margin | -545.6% | -20153.0% | 12023.6% | -13301.2% | -7225.9% | -12622.6% | -2727.5% | 1878.3% | -6255.3% | 719.5% | -1675.3% | 32747.6% |
| Free cash flow margin | 1691.9% | -18788.0% | -6550.8% | -10076.0% | -12317.8% | -9604.5% | -2290.3% | -2318.5% | -5984.4% | -2425.5% | -1206.3% | -1354.6% |
| Current ratio | 15.56 | 16.72 | 18.37 | 30.66 | 33.70 | 40.54 | 33.47 | 37.91 | 10.43 | 27.91 | 25.24 | 27.79 |
| Debt to equity | - | - | - | - | - | - | - | - | - | 0.05 | 0.07 | 0.06 |
Source: XBRL data Roivant Sciences Ltd. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ROIV | $41.08M | +102.1% | -$445.12M | -1083.5% | $29.38B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |